Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Condition:   Triple Negative Breast Cancer Interventions:   Drug: epirubicin hydrochloride;   Drug: Cyclophosphamide;   Drug: Albumin bound paclitaxel;   Drug: Toripalimab Sponsor:   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials